+

WO2025059665A1 - Traitement en série par toxine botulique contre la dystonie cervicale - Google Patents

Traitement en série par toxine botulique contre la dystonie cervicale Download PDF

Info

Publication number
WO2025059665A1
WO2025059665A1 PCT/US2024/046938 US2024046938W WO2025059665A1 WO 2025059665 A1 WO2025059665 A1 WO 2025059665A1 US 2024046938 W US2024046938 W US 2024046938W WO 2025059665 A1 WO2025059665 A1 WO 2025059665A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
efficacy
botulinum toxin
subsequent
peak
Prior art date
Application number
PCT/US2024/046938
Other languages
English (en)
Inventor
Todd Gross
Conor GALLAGHER
Rashid KAZEROONI
Rob BANCROFT
David Hollander
Original Assignee
Revance Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics, Inc. filed Critical Revance Therapeutics, Inc.
Publication of WO2025059665A1 publication Critical patent/WO2025059665A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Definitions

  • This invention relates to methods to treat cervical dystonia with injectable compositions comprising botulinum toxin that may be administered to a subject suffering from such malady.
  • the methods described herein involve a series of treatment sessions with a botulinum toxin composition that can be used to achieve for the patient maintenance of a peak treatment effect or within a narrow range thereof over the course of a plurality of treatment sessions.
  • Cervical dystonia is an extremely painful, chronic neurological movement disorder where the neck and shoulder muscles contract involuntarily and contort, causing abnormal movements and awkward posture of the head and neck such as the head to twist or turn to the left or right (torticollis), upwards (retrocollis), downwards (antecollis) or sideways (laterocollis).
  • the movements may be sustained (tonic), jerky (clonic), or a combination.
  • Cervical dystonia also referred to as neck dystonia or spasmodic torticollis
  • Cervical dystonia may be primary (meaning that it is the only apparent neurological disorder, with or without a family history) or may be brought about by secondary causes (such as physical trauma) and is often attributed to nervous system damage caused by a stroke, disease or trauma.
  • secondary causes such as physical trauma
  • Those with a family history of cervical dystonia or some other type of dystonia are at higher risk of developing the disorder.
  • Cervical dystonia is the third most common movement disorder following essential tremor and Parkinson’s disease. An estimated 3 in every 10,000 people are known to suffer from cervical dystonia. The number of cases reported in North America alone is approximately 300,000.
  • Treatments for cervical dystonia include oral medications, botulinum toxin injections, surgery, and complementary therapies.
  • the most commonly prescribed treatment for cervical dystonia is the use of botulinum toxin, typically type A (although Type B has also been used), which can reduce its signs and symptoms.
  • Botulinum toxin can help block the communication between the nerve and the muscle and may alleviate abnormal movements and postures.
  • the number of injections is typically based on the severity of the dystonia. Doctors injecting the toxin may select the muscles to be injected by observing abnormal postures or movements and feeling for the muscle spasm or by using an electromyography machine to measure muscle activity. Each muscle affected by dystonia typically has to be injected separately.
  • the present disclosure is directed to a method of treating cervical dystonia in a subject, the method comprising administering a treatment regimen to said subject wherein the treatment regimen comprises: administering a plurality of botulinum toxin treatments to treat cervical dystonia separated by an interval, wherein the interval between each of said botulinum treatments is at least 12 weeks; and wherein each treatment comprises injecting a therapeutically effective amount of botulinum toxin into one or more muscles contributing to cervical dystonia symptoms of said subject; and wherein a treatment administered subsequent to a prior treatment is administered when remaining efficacy of the prior treatment is greater than 40% of its peak efficacy.
  • a method of treating cervical dystonia (CD) in a subject comprising: administering a treatment to a subject that is prior to a subsequent treatment, wherein the treatment comprises injecting a therapeutically effective amount of botulinum toxin in a pharma composition to a plurality of muscles to treat torticollis only and administering the subsequent treatment to the subject, wherein the subsequent treatment comprises injecting a therapeutically effective amount of the botulinum toxin composition to a plurality of muscles to treat laterocollis, antecollis, or retrocollis and optionally torticollis.
  • Figure 1 depicts injectable muscles as defined by the Study Design described in the Example Section.
  • Figures 2 to 4 each show a treatment effect of patients with three or four serial treatments with a botulinum toxin composition described herein.
  • This invention relates to treatment regimens wherein the timing of a retreatment and the dose amount is such that the there is a significant amount of remaining efficacy from the prior treatment at the time of retreatment, wherein the time of retreatment is 12 or more weeks from the prior treatment.
  • the remaining efficacy is greater than 40% of peak treatment effect or more specifically, greater than 50%, 60% of peak treatment effect, or more specifically, 70% of peak treatment effect. In other words, a significant amount of effect remains in the patient at the time of retreatment even though the retreatment time is beyond 12 weeks.
  • Peak efficacy is when the botulinum toxin treatment is having its maximum effect on the patient. Typically, this is achieved around 4-7 weeks after injection and can be sustained for multiple weeks.
  • TWSTRS or other suitable scales known to a person skilled in the art can be used.
  • TWSTRS score of patient within the time period of 4 weeks to 7 weeks post treatment can be used to determine the state of a subject’s symptoms at “peak efficacy”.
  • the patient s symptomatic state at peak efficacy, at baseline, and at the particular post-treatment time of interest can be used.
  • a patient's baseline is the state of symptoms without any treatment effect, e.g., when there is no toxin effect on the muscles.
  • the percent of remaining treatment effect at time X is essentially the ratio of the difference between the symptomatic state at X and the baseline to difference between the symptomatic state at peak effect and the baseline.
  • the percent of treatment effect loss at time X is essentially the ratio of the difference between the symptomatic state at X and the peak effect to difference between the symptomatic state at peak effect and the baseline.
  • a patient is preferably within the peak effect of the treatment but near its end or has at least 60% of peak efficacy, or more preferably, at least 70, 80, 90, or 100% of peak efficacy.
  • dose can impact what the symptomatic state is at “peak efficacy”.
  • TWSTRS scores can be lower for a patient when the amount of toxin administered is higher.
  • the dose amount and the interval of time between treatments can be adjusted to achieve a symptomatic state that does not significantly deviate from the symptomatic state at peak efficacy and that symptomatic state at peak efficacy can be maximized without significant adverse events to the patient.
  • a treatment regimen to treat cervical dystonia comprises administering a plurality of botulinum toxin treatments separated by an interval.
  • Each treatment comprises injecting a therapeutically effective amount of botulinum toxin into one or more muscles contributing to cervical dystonia symptoms of said subject.
  • the interval between each of said botulinum treatments must be at least 12 weeks.
  • the interval between treatments is approximately the time from treatment to about 3 to 21 days before efficacy begins to wane for a treatment. In this manner, as the prior treatment effect begins to wane, the retreatment effect starts its rise and the subject’s symptom state remains near the state at peak efficacy.
  • the amount of an interval can vary between subjects depending on a particular patient’s response to toxin but is usually between 12 to 36 weeks (e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 weeks).
  • a treatment that is administered subsequent to a prior treatment is administered when the remaining efficacy of the prior treatment is greater than 20% or more preferably greater than 40% of its peak efficacy.
  • the subsequent treatment can be administered when remaining efficacy of the prior treatment is greater than 50% of its peak efficacy or greater than 60% of its peak efficacy or greater than 70% of its peak efficacy or greater than 80% of its peak efficacy or greater than 90% of its peak efficacy or before peak efficacy begins to wane.
  • the subsequent treatment can be administered when remaining efficacy of the prior treatment is 40% to 90% or 50% to 90% or 60% to 90% or 70% to 90% of its peak efficacy.
  • the dose can be titrated over time to determine the minimal amount of toxin that is needed to have the maximum treatment effect (e.g., lowest TWSTRS score possible) at peak efficacy.
  • the therapeutically effective amount of the subsequent treatment can be reduced from that of the therapeutically effective amount of the prior treatment but because of the overlapping effect of the treatments a peak efficacy of the subsequent treatment is approximately equal to or is greater than the peak efficacy of the prior treatment.
  • the therapeutically effective amount of the subsequent treatment can be increased from that of the therapeutically effective amount of the prior treatment to assess if the subj ect’ s symptomatic state at peak efficacy can be improved.
  • a high dose such as 300U for a prior treatment and reduce the amount of toxin after the prior treatment to determine whether there is a maintenance of peak treatment effect at the lower dose.
  • Such strategy mayshorten the interval of time to achieve maintenance of the peak treatment effect or maintain an effect within a narrow range thereof over the entire course of a plurality of treatment sessions.
  • a narrow range of a peak treatment effect can be within 30%, 25%, 20%, or 15% of the peak treatment effect as compared to baseline measured by TWSTRS or another method of scaling cervical dystonia in a subject.
  • the muscles treated at different treatments can be varied, for example, when some muscles exhibit a longer duration of response to toxin than other muscles.
  • the one or more muscles injected in a subsequent treatment can be different than the one or more muscles of a prior treatment or can be a subgroup or an expanded group thereof.
  • splenius capitis, trapezius and levator scapulae on the same side and the sternocleidomastoid on the opposite side (or a sub-group thereof) may be treated in each treatment session but additional muscles can be treated in every other session.
  • the method can further comprise administering a treatment following the subsequent treatment to the subject to treat CD, wherein the treatment following the subsequent treatment is administered when remaining efficacy of the subsequent treatment is greater than 20%, 30%, 40%, 50%, 60%, 70%, or 80%, 90% of its peak efficacy or at peak efficacy.
  • the dosage can again be reduced or increased from the prior treatment, wherein the symptomatic state at peak efficacy of the subsequent treatment is the same as or improved from the state at the peak efficacy of the prior treatment.
  • the one or more muscles injected in the treatment following the subsequent treatment can be varied from the prior treatment as described above.
  • Treatment regimens as described herein can lead to the subject’s symptomatic state at peak efficacy improving with the first 2-6 session until a maximum treatment state at peak efficacy is achieved at which point the patient can receive a consistent dose, which may also be at a consistent interval.
  • the subsequent treatment is administered when remaining efficacy of the prior treatment is greater than 80% of its peak efficacy and wherein a peak efficacy of the subsequent treatment is approximately equal to or better than the peak efficacy of the prior treatment.
  • repeated administrations following the subsequent treatment or the treatment following the subsequent treatement, maintain a peak treatment effect (also referred to as maximum treatment state) or maintain an effect within a narrow range of the peak treatment effect over the course of the repeated administrations.
  • a narrow range of a peak treatment effect can be within 30%, 25%, 20%, or 15% of the peak treatment effect as compared to baseline measured by TWSTRS or another method of scaling cervical dystonia in a subject.
  • a method of treating cervical dystonia (CD) in a subject can comprise a treatment regimen wherein the muscles targeted differ between two consecutive treatments and the muscle group alternates.
  • the method can comprise administering a therapeutically effective amount of botulinum toxin in a pharmaceutical composition to a plurality of muscles to treat torticollis only and administering in a subsequent treatment to the subject a therapeutically effective amount of the botulinum toxin composition to a plurality of muscles to treat laterocollis, antecollis, or retrocollis and optionally torticollis.
  • the subsequent treatment is to treat laterocollis only.
  • the subsequent treatment is to treat laterocollis and torticollis.
  • the subsequent treatment is administered when remaining efficacy of the prior treatment is greater than 60%, 70, 80, or 90% or atl00% of its peak efficacy.
  • the treatment interval can be at least 12 weeks after the administration of the prior treatment.
  • a composition that can be used with treatment regimens described herein are those with a duration of effect at least greater than 16 weeks, such as greater than 18, 20, 24, 28, 30 weeks, or more.
  • Suitable composition may be used as injectable applications for providing a botulinum toxin to a subject with cervical dystonia as described herein.
  • a composition in accordance with the present disclosure comprises a positively charged peptide carrier to which botulinum toxin non-covalently associates.
  • a suitable composition can also have an improved safety profile, including fewer adverse events, over other compositions and methods of delivery of botulinum toxin so that shortened dosing intervals are well tolerated.
  • suitable compositions are injectable and provide a duration of effect that lasts 16 weeks, 18 weeks, 20 weeks, or 24 weeks in subjects to whom such compositions, particularly those comprising botulinum toxin in amounts of 100U to 500 U, are administered by injection for the treatment of cervical dystonia.
  • botulinum toxin may refer to any of the known types of botulinum toxin (e.g., 150 kD botulinum toxin protein molecules associated with the different serotypes of C. botulinum), whether produced by the bacterium or by recombinant techniques, as well as any such types that may be subsequently discovered including newly discovered serotypes, and engineered variants or fusion proteins.
  • botulinum neurotoxins Currently seven immunologically distinct botulinum neurotoxins have been characterized, namely botulinum neurotoxin serotypes A, B, C, D, E, F and G, each of which is distinguished by neutralization with type-specific antibodies.
  • botulinum toxin serotypes are commercially available, for example, from Sigma-Aldrich (St. Louis, MO) and from Metabiologics, Inc. (Madison, WI), as well as from other sources.
  • the different serotypes of botulinum toxin vary in the animal species that they affect and in the severity and duration of the paralysis they evoke.
  • At least two types of botulinum toxin, types A and B, are available commercially in formulations for treatment of certain conditions.
  • Type A for example, is contained in preparations of Allergan having the trademark BOTOX®, of Ipsen having the trademark DYSPORT®, and of Revance having the trademark DAXXIFY®, and type B is contained in preparations of Elan having the trademark MYOBLOC®.
  • botulinum toxin used in the compositions of this invention can alternatively refer to a botulinum toxin derivative, that is, a compound that has botulinum toxin activity but contains one or more chemical or functional alterations on any part or on any amino acid chain relative to naturally occurring or recombinant native botulinum toxins.
  • the botulinum toxin may be a modified neurotoxin that is a neurotoxin which has at least one of its amino acids deleted, modified or replaced, as compared to a native form, or the modified neurotoxin can be a recombinantly produced neurotoxin or a derivative or fragment thereof.
  • the botulinum toxin may be one that has been modified in a way that, for instance, enhances its properties or decreases undesirable side effects, but that still retains the desired botulinum toxin activity.
  • the botulinum toxin used in this invention may be a toxin prepared using recombinant or synthetic chemical techniques, e.g. a recombinant peptide, a fusion protein, or a hybrid neurotoxin, for example prepared from subunits or domains of different botulinum toxin serotypes (See, U.S. Patent No. 6,444,209, for instance).
  • the botulinum toxin may also be a portion of the overall molecule that has been shown to possess the necessary botulinum toxin activity, and in such case may be used per se or as part of a combination or conjugate molecule, for instance a fusion protein.
  • the botulinum toxin may be in the form of a botulinum toxin precursor, which may itself be non-toxic, for instance a non-toxic zinc protease that becomes toxic on proteolytic cleavage.
  • botulinum toxin complex or “toxin complex” as used herein refers to the approximately 150 kD botulinum toxin protein molecule (belonging to any one of botulinum toxin serotypes A-G), along with associated endogenous non-toxin proteins (i.e., hemagglutinin protein and non-toxin non-hemagglutinin protein produced by Clostridium botulinum bacteria). Note, however, that the botulinum toxin complex need not be derived from Clostridium botulinum bacteria as one unitary toxin complex.
  • botulinum toxin or modified botulinum toxin may be recombinantly prepared first and then subsequently combined with the non-toxin proteins.
  • Recombinant botulinum toxin can also be purchased (e.g., from List Biological Laboratories, Campbell, CA) and then combined with non-toxin proteins.
  • Suitable compositions can comprise botulinum toxin that is a “reduced botulinum toxin complex”, in which the botulinum toxin complexes have reduced amounts of endogenous non-toxin protein compared to the amounts naturally found in botulinum toxin complexes produced by Clostridium botulinum bacteria.
  • reduced botulinum toxin complexes are prepared using any conventional protein separation method to extract a fraction of the hemagglutinin protein or non-toxin non-hemagglutinin protein from botulinum toxin complexes derived from Clostridium botulinum bacteria.
  • reduced botulinum toxin complexes may be produced by dissociating botulinum toxin complexes through exposure to red blood cells at a pH of 7.3 (e.g., see EP 1514556 Al, hereby incorporated herein by reference). HPLC, dialysis, columns, centrifugation, and other methods for extracting proteins from proteins can be used.
  • the reduced botulinum toxin complexes are to be produced by combining synthetically produced botulinum toxin with non-toxin proteins, one may simply add less hemagglutinin or non-toxin, non-hemagglutinin protein to the mixture than what would be present for naturally occurring botulinum toxin complexes.
  • any of the non-toxin proteins in the reduced botulinum toxin complexes according to the invention may be reduced independently by any amount.
  • one or more non-toxin proteins are reduced by at least about 0.5%, 1%, 3%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% compared to the amounts normally found in botulinum toxin complexes.
  • Clostridium botulinum bacteria produce seven different serotypes of toxin and commercial preparations are manufactured with different relative amounts of non-toxin proteins (i.e.
  • MYOBLOCTM has 5000 U of Botulinum toxin type B per ml with 0.05% human serum albumin, 0.01 M sodium succinate, and 0.1 M sodium chloride.
  • DYSPORTTM has 500 U of botulinum toxin type A-hemagglutinin complex with 125 mcg albumin and 2.4 mg lactose.
  • substantially all of the non-toxin protein e.g., greater than 95%, 96%, 97%, 98% or 99% of the hemagglutinin protein and non-toxin non-hemagglutinin protein
  • substantially all of the non-toxin protein that would normally be found in botulinum toxin complexes derived from Clostridium botulinum bacteria is removed from the botulinum toxin complex.
  • the amount endogenous non- toxin proteins may be reduced by the same amount in some cases, this invention also contemplates reducing each of the endogenous non-toxin proteins by different amounts, as well as reducing at least one of the endogenous non-toxin proteins, but not the others.
  • a form of botulinum toxin wherein substantially all of the non-toxin proteins have been removed is referred to as a 150 kD botulinum toxin.
  • a preferred composition suitable with the methods described herein is a botulinum toxin-containing composition that is stabilized a positively charged carrier (e.g., peptide).
  • a positively charged carrier e.g., peptide
  • a positively charged carrier molecule having protein transduction domains or efficiency groups, as described herein has been found suitable as a transport system for a botulinum toxin, enabling toxin to be injected with improved penetration to target structures such as muscles. The transport occurs without covalent modification of the botulinum toxin.
  • the positively charged carriers of the invention may stabilize the botulinum toxin against degradation.
  • the hemagglutinin protein and non-toxin, nonhemagglutinin protein that are normally present to stabilize the botulinum toxin may be reduced or omitted entirely.
  • albumin that is normally added during manufacturing to toxin formulations can be omitted.
  • positively charged or cationic in connection with the term “carrier”, it is meant that the carrier has a positive charge under at least some solution-phase conditions, more preferably, under at least some physiologically compatible conditions. More specifically, “positively charged” and “cationic” as used herein, means that the group in question contains functionalities that are charged under all pH conditions, for instance, a quaternary amine, or contains a functionality which can acquire positive charge under certain solution-phase conditions, such as pH changes in the case of primary amines. More preferably, “positively charged” or “cationic” as used herein refers to those groups that have the behavior of associating with anions over physiologically compatible conditions.
  • Polymers with a multiplicity of positively-charged moieties need not be homopolymers, as will be apparent to one skilled in the art.
  • Other examples of positively charged moieties are well known in the prior art and can be employed readily, as will be apparent to those skilled in the art.
  • the positively-charged carrier (also referred to as a “positively charged backbone”) is typically a chain of atoms, either with groups in the chain carrying a positive charge at physiological pH, or with groups carrying a positive charge attached to side chains extending from the backbone.
  • the positively charged backbone is a cationic peptide.
  • the term “peptide” refers to an amino acid sequence, but carries no connotation with respect to the number of amino acid residues within the amino acid sequence. Accordingly, the term “peptide” may also encompass polypeptides and proteins.
  • the positively charged backbone itself will not have a defined enzymatic or therapeutic biologic activity.
  • the backbone is a linear hydrocarbon backbone which is, in some embodiments, interrupted by heteroatoms selected from nitrogen, oxygen, sulfur, silicon and phosphorus.
  • the majority of backbone chain atoms are usually carbon.
  • the backbone will often be a polymer of repeating units (e.g., amino acids, poly(ethyleneoxy), poly(propyleneamine), polyalkyleneimine, and the like) but can be a heteropolymer.
  • the positively charged backbone is a polypropyleneamine wherein a number of the amine nitrogen atoms are present as ammonium groups (tetra-substituted) carrying a positive charge.
  • the positively charged backbone is a nonpeptidyl polymer, which may be a hetero- or homo-polymer such as a poly alkyleneimine, for example a polyethyleneimine or polypropyleneimine, having a molecular weight of from about 10,000 to about 2,500,000, preferably from about 100,000 to about 1,800,000, and most preferably from about 500,000 to about 1,400,000.
  • the backbone has attached a plurality of side-chain moieties that include positively charged groups (e.g., ammonium groups, pyridinium groups, phosphonium groups, sulfonium groups, guanidinium groups, or amidinium groups).
  • the sidechain moieties in this group of embodiments can be placed at spacings along the backbone that are consistent in separations or variable. Additionally, the length of the sidechains can be similar or dissimilar.
  • the sidechains can be linear or branched hydrocarbon chains having from one to twenty carbon atoms and terminating at the distal end (away from the backbone) in one of the above-noted positively charged groups.
  • the association between the positively charged carrier and the botulinum toxin is by non-covalent interaction, non-limiting examples of which include ionic interactions, hydrogen bonding, van der Waals forces, or combinations thereof. Examples of postively charged backbones and efficiency groups for use of the invention are described in U.S. Patent Nos.
  • the positively charged backbone is a polypeptide having multiple positively charged sidechain groups (e.g., lysine, arginine, ornithine, homoarginine, and the like).
  • the polypeptide has a molecular weight from about 100 to about 1,500,000, more preferably from about 500 to about 1,200,000, most preferably from about 1000 to about 1,000,000.
  • the sidechains can have either the D- or L-form (R or S configuration) at the center of attachment.
  • the polypeptide has a molecular weight from about 500 to about 5000, more preferably from 1000 to about 4000, more preferably from 2000 to about 3000. In other preferred embodiments, the polypeptide comprises 10 to 20 amino acids, or 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids, preferably polylysine.
  • the backbone may comprise amino acid analogs and/or synthetic amino acids.
  • the backbone may also be an analog of a polypeptide such as a peptoid.
  • a polypeptide such as a peptoid.
  • a peptoid is a polyglycine in which the sidechain is attached to the backbone nitrogen atoms rather than the a-carbon atoms.
  • a portion of the sidechains will typically terminate in a positively charged group to provide a positively charged backbone component.
  • Synthesis of peptoids is described in, for example, U.S. Patent No. 5,877,278, which is hereby incorporated by reference in its entirety.
  • positively charged backbones that have a peptoid backbone construction are considered “non-peptide” as they are not composed of amino acids having naturally occurring sidechains at the alpha-carbon locations.
  • sidechain groups can be appended that carry a positively charged group.
  • the sulfonamide-linked backbones (— SO2NH— and — NHSO2— ) can have sidechain groups attached to the nitrogen atoms.
  • the hydroxyethylene (-CH(OH)CH2— ) linkage can bear a sidechain group attached to the hydroxy substituent.
  • One of skill in the art can readily adapt the other linkage chemistries to provide positively charged sidechain groups using standard synthetic methods.
  • the positively charged backbone is a polypeptide having protein transduction domains (also referred to as efficiency groups).
  • an efficiency group or protein transduction domain is any agent that has the effect of promoting the translocation of the positively charged backbone through a tissue or cell membrane.
  • Non-limiting examples of protein transduction domains or efficiency groups include -(gly)ni-(arg) n 2 (SEQ ID NO: 5), HIV- TAT or fragments thereof, or the protein transduction domain (PTD) of Antennapedia, or a fragment thereof, in which the subscript nl is an integer of from 0 to 20, more preferably 0 to 8, still more preferably 2 to 5, and the subscript n2 is independently an odd integer of from about 5 to about 25, more preferably about 7 to about 17, most preferably about 7 to about 13.
  • the HIV-TAT fragment does not contain the cysteine-rich region of the HIV- TAT molecule, in order to minimize the problems associated with disulfide aggregation.
  • the fragments of the HIV-TAT and Antennapedia protein transduction domains retain the protein transduction activity of the full protein. Still further preferred are those embodiments in which the HIV-TAT fragment has the amino acid sequence (gly) P -RGRDDRRQRRR-(gly) q (SEQ ID NO: 1), (gly) P -YGRKKRRQRRR-(gly)q (SEQ ID NO: 2) or (gly) P -RKKRRQRRR-(gly) q (SEQ ID NO: 3) wherein the subscripts p and q are each independently an integer of from 0 to 20, or wherein p and q are each independently the integer 1.
  • the fragment or efficiency group is attached to the backbone via either the C-terminus or the N-terminus of the fragment or amino acid sequence of the efficiency group.
  • p is one and q is zero or p is zero and q is one.
  • Preferred HIV-TAT fragments are those in which the subscripts p and q are each independently integers of from 0 to 8, more preferably 0 to 5.
  • the positively charged side chain or branching group is the Antennapedia (Antp) protein transduction domain (PTD), or a fragment thereof that retains activity. These are known in the art, for instance, from Console et al., J. Biol. Chem.
  • the positively charged carrier is a positively charged peptide having the amino acid sequence RKKRRQRRR-G-(K)15-G-RKKRRQRRR (SEQ ID NO: 4); or a positively charged peptide having the amino acid sequence YGRKKRRQRRR-G-(K)is-G-YGRKKRRQRRR (SEQ ID NO: 7); or a positively charged peptide having the amino acid sequences RGRDDRRQRRR-G-(K)is- G-RGRDDRRQRRR (SEQ ID NO: 8) for use in the compositions and methods of the invention.
  • the backbone portion is a polylysine and positively charged protein transduction domains are attached to the lysine sidechain amino groups or to the C- or N- termini.
  • the polylysine may have a molecular weight that is at least 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, or 6000 D, and less than about 2,000,000, 1,000,000, 500,000, 250,000, 100,000, 75,000, 50,000, and 25,000 D.
  • polylysine polypeptide having 10 to 20 lysines (SEQ ID NO: 9), more preferably, 15 lysines.
  • the polylysine contemplated by this invention can be any of the commercially available (Sigma Chemical Company, St. Louis, Mo., USA) polylysines such as, for example, polylysine having MW>70,000, polylysine having MW of 70,000 to 150,000, polylysine having MW 150,000 to 300,000 and polylysine having MW>3 00,000.
  • the selection of an appropriate polylysine will depend on the remaining components of the composition and will be sufficient to provide an overall net positive charge to the composition and provide a length that is preferably from one to four times the combined length of the negatively charged components.
  • Preferred positively charged protein transduction domains or efficiency groups include, for example, -gly-gly-gly-arg-arg-arg-arg-arg (-GlysArg? (SEQ ID NO: 10)) or HIV-TAT.
  • the positively charged backbone is a polyalkyleneimine, non-limiting examples of which include polyethyleneimine, polypropyleneimine, and polybutyleneimine.
  • the polyalkyleneimine has a molecular weight of at least 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, or 6000 D, and less than about 2,000,000, 1,000,000, 500,000, 250,000, 100,000, 75,000, 50,000, and 25,000 D. Within the range of 100 to 2,000,000 D, it is contemplated that the lower and/or upper range may be increased or decreased, respectively, by 100, with each resulting sub-range being a specifically contemplated embodiment of the invention.
  • the carrier is a relatively short polylysine or polyethyleneimine (PEI) backbone (which may be linear or branched) and which has positively charged branching groups.
  • PEI polyethyleneimine
  • the backbone will have a molecular weight of less than 75,000 D, more preferably less than 30,000 D, and most preferably, less than 25,000 D.
  • the non-native molecules are cationic peptides that have no inherent botulinum-toxin-like activity and that also contain one or more protein transduction domains as described herein. Without wishing to be bound by any particular scientific theory, it is believed that certain peptides can enhance tissue penetration of molecules associated in complex after injection, while enhancing stabilization of the botulinum toxin in skin and in vitro.
  • tissue penetration afforded by certain peptides in particular affords reduced antigenicity, a better safety profile, enhanced potency, faster onset of clinical efficacy or longer duration of clinical efficacy compared to conventional commercial botulinum toxin complexes that are bound to exogenous albumin (e.g., BOTOX® or MYOBLOC®).
  • exogenous albumin e.g., BOTOX® or MYOBLOC®
  • the concentration of positively charged carriers in the compositions according to the invention is sufficient to enhance the delivery of the botulinum toxin to molecular targets such as, for example, motor nerve plates.
  • the penetration rate follows receptor-mediated kinetics, such that tissue penetration increases with increasing amounts of penetration-enhancing-molecules up to a saturation point, upon which the transport rate becomes constant.
  • the amount of added penetration-enhancing-molecules is equal to the amount that maximizes penetration rate right before saturation.
  • a useful concentration range for the positively charged carrier (or carrier peptide) in the injectable compositions of this invention is about 0.1 pg of carrier per Unit (U) of botulinum toxin (0.1 pg/U) to about 1.0 mg per Unit (mg/U) of the botulinum toxin as described herein.
  • a useful concentration range for the positively charged carrier (or carrier peptide) in the topical compositions of the invention is about 1.0 pg/U to 0.5 mg/U of botulinum toxin (amount of carrier/U of botulinum toxin).
  • the positively charged carrier is present in the injectable compositions of the invention in the range of, for example, 1 ng/U to 300 ng/U or 10 ng/U to 200 ng/U of botulinum toxin, or in the range of 1 ng/U to 1000 ng/U of botulinum toxin; or in the range of 0.1 ng/U to 10,000 ng/U of botulinum toxin.
  • the amount of positively charged carrier (or carrier peptide) to Units of botulinum toxin present in the compositions of the invention is, by way of nonlimiting example, 0.5, 1, 2, 5, 10, 20, 30, 40, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200 ng of carrier per Unit of botulinum toxin (ng/U), or any amount therebetween.
  • the botulinum toxin is of serotype A
  • LDso assays median lethality assays
  • U units of botulinum toxin activity
  • LDso assays median lethality assays
  • Doses of all commercially available botulinum toxins are expressed in terms of units of biologic activity.
  • one unit of botulinum toxin corresponds to the calculated median intraperitoneal lethal dose (LD50) in female Swiss-Webster mice. See, Hoffman, R.O. et al., 1986, Int. Ophthalmol.
  • a suitable method for determining botulinum toxin units for a botulinum toxin component of the compositions of the invention is as follows: Forty-eight (48) female CD-I mice weighing 17-23 grams are randomly assigned to six doses of the test article (1.54, 1.31, 1.11, 0.95, 0.80, and 0.68 U/0.5 m ), eight (8) animals per dose group.
  • the test article refers to the botulinum toxin preparation or sample being assayed or tested.
  • the animals are housed eight per cage and are weighed within 24 hours of dosing with the test article. On the day of dosing, the test article is diluted to the appropriate concentrations in isotonic saline (0.9% NaCl). Each animal is administered 0.5 mb of diluted test article via intraperitoneal injection. After injection, mice are returned to the cage and fatalities are recorded daily for three days. Lethality is scored 72 hours post injection and the results are analyzed by probit or logistic analysis to derive the LDso value relative to a reference standard that is assessed using the same dosing regimen.
  • the reference standard is a specifically qualified and calibrated lot of the same composition of the invention that is used for comparison to derive relative potency of the test article.
  • the determined LDso value is then corrected for the cumulative dilutions performed to assign a relative potency value for the neat (undiluted) test article.
  • compositions of this invention are preferably in a form that permits injection into the skin or epithelium of subjects or patients.
  • the term “in need” is meant to include both pharmaceutical or health-related needs (e.g., treating conditions involving undesirable dystonic contractions or muscle spasms).
  • the compositions are prepared by mixing the botulinum toxin (either containing the associated non-toxin proteins or reduced associated non-toxin proteins) with the positively charged carrier, and usually with one or more additional pharmaceutically acceptable carriers or excipients.
  • they may contain an aqueous pharmaceutically acceptable diluent, such as buffered saline (e.g., phosphate buffered saline).
  • compositions may contain other ingredients typically found in injectable pharmaceutical or cosmeceutical compositions, including a dermatologically or pharmaceutically acceptable carrier, vehicle or medium that is compatible with the tissues to which it will be applied.
  • pharmaceutically acceptable means that the compositions or components thereof so described are suitable for use in contact with these tissues or for use in patients in general without undue toxicity, incompatibility, instability, allergic response, and the like.
  • compositions of the invention may comprise any ingredient conventionally used in the fields under consideration.
  • compositions of this invention may include solutions, emulsions (including microemulsions), suspensions, gels, powders, or other typical solid or liquid compositions used for injection to muscle and other tissues where the compositions may be used.
  • the compositions of the invention are present in low-viscosity, sterile formulations suitable for injection with a syringe.
  • the terms compositions and formulations are essentially interchangeable when referring to the compositions and formulations according to the present invention.
  • the compositions of the invention may be in the form of a lyophilized powder that is reconstituted using a pharmaceutically acceptable liquid diluent prior to injection.
  • the lyophilized powder is reconstituted with a liquid diluent to form an injectable formulation with a viscosity of about 0.1 to about 2000 cP, more preferably about 0.2 to about 500 cP, even more preferably about 0.3 to about 50 cP, and even more preferably about 0.4 to about 2.0 cP.
  • compositions of the invention may contain, in addition to the botulinum toxin and positively charged carrier, other ingredients typically used in such products, such as antimicrobials, hydration agents, tissue bulking agents or tissue fillers, preservatives, emulsifiers, natural or synthetic oils, solvents, surfactants, detergents, gelling agents, antioxidants, fillers, thickeners, powders, viscosity-controlling agents and water, and optionally including anesthetics, anti-itch actives, botanical extracts, conditioning agents, minerals, polyphenols, silicones or derivatives thereof, vitamins, and phytomedicinals.
  • other ingredients typically used in such products such as antimicrobials, hydration agents, tissue bulking agents or tissue fillers, preservatives, emulsifiers, natural or synthetic oils, solvents, surfactants, detergents, gelling agents, antioxidants, fillers, thickeners, powders, viscosity-controlling agents and water, and optionally including anesthetics, anti-itch actives,
  • the injectable compositions according to this invention may be in the form of controlled-release or sustained-release compositions which comprise botulinum toxin and positively charged carrier encapsulated or otherwise contained within a material such that they are released within the tissue in a controlled manner over time.
  • the composition comprising the botulinum toxin and positively charged carrier may be contained within matrixes, liposomes, vesicles, microcapsules, microspheres and the like, or within a solid particulate material, all of which is selected and/or constructed to provide release of the botulinum toxin over time.
  • the botulinum toxin and the positively charged carrier may be encapsulated together (i.e., in the same capsule) or separately (i.e., in separate capsules).
  • compositions of the invention comprise compositions (or formulations) comprising a botulinum toxin as described herein, a positively charged carrier (or peptide) as described herein, a non-reducing di saccharide or a non-reducing tri saccharide, a nonionic surfactant, and a physiologically compatible buffer, which is capable of maintaining a suitable pH, such as a pH in the range of pH 4.5 to pH 7.5, or pH 4.5 to pH 6.8, or pH 4.5 to pH 6.5. It is to be understood that a suitable pH also includes the upper and lower pH values in the range, e.g., a pH of 6.5 or a pH of 7.5.
  • the concentration of the non-reducing sugar in the reconstituted composition is in the range of 10% through 40% (w/v) and the concentration of the non-ionic surfactant is in the range of 0.005% through 0.5% (w/v).
  • the compositions can in powder form, preferably by lyophilization, to produce stabilized solid compositions, which may thereafter be reconstituted for use, for example, using sterile saline or other known physiologically and pharmaceutically acceptable diluents, excipients, or vehicles, especially those known for use in injectable formulations.
  • the dried, e.g., lyophilized, solid compositions are noncrystalline and amorphous solid compositions, and may be in the form of powders, for example.
  • compositions of the invention do not include animal protein-derived products, such as albumin.
  • animal protein-derived products such as albumin.
  • Compositions that are suitable for the invention are also described in U.S. Patent No. 9,340,587 B2, the entire contents of which are incorporated herein by reference.
  • the compositions comprise botulinum toxin of serotype A.
  • the compositions comprise botulinum toxin of serotype A which has a molecular weight of 150 kDa.
  • the compositions of the invention contain a non-reducing sugar, which is preferably a disaccharide, non-limiting examples of which include trehalose, including its anhydrous and hydrated forms, or sucrose, as well as combinations thereof.
  • a disaccharide non-limiting examples of which include trehalose, including its anhydrous and hydrated forms, or sucrose, as well as combinations thereof.
  • the hydrated form of trehalose, trehalose-dihydrate is preferable.
  • the compositions contain a trisaccharide, a non-limiting example of which is raffinose.
  • the concentration of the non-reducing sugar, preferably a disaccharide, e.g., sucrose, in the compositions of the invention are in the range of 10% to 40% (w/v), preferably 10% to 25% (w/v), more preferably 15% to 20% (w/v).
  • the concentration of the non-reducing sugar, preferably a disaccharide, e.g., sucrose is 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20% (w/v).
  • the compositions of the invention may include any non-ionic surfactant that has the ability to stabilize botulinum toxin and that is suitable for pharmaceutical use.
  • the non-ionic surfactant is a polysorbate, such as, by way of nonlimiting example, polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80.
  • the non-ionic surfactant is a sorbitan ester, non-limiting examples of which include SPAN® 20, SPAN® 60, SPAN® 65, and SPAN® 80.
  • the non-ionic surfactants Triton® X-100 or NP-40 may also be used.
  • a combination of the different non-ionic surfactants may be used.
  • the non-ionic surfactant is a polysorbate, a poloxamer and/or a sorbitan; polysorbates and sorbitans are particularly preferred.
  • the non-ionic surfactant is present in the compositions of the invention in the range of 0.005% to 0.5%, or in the range of 0.01% to 0.2%, or in the range of 0.02% to 0.1% or in the range of 0.05 to 0.08%, inclusive of the upper and lower values.
  • compositions of the invention may contain a non-ionic surfactant in the amount of 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.10%, 0.11%, 0.12%, 0.13%, 0.14%, or 0.15%.
  • any physiologically compatible buffer capable of maintaining the pH in the above ranges is suitable for use.
  • buffers include salts of citric acid, acetic acid, succinic acid, tartaric acid, maleic acid, and histidine.
  • suitable buffer concentrations include buffer concentrations in the range of 0.400% to 0.600%; 0.450% to 0.575%, or 0.500% to 0.565%.
  • the compositions of the invention may also comprise a mixture of buffer salts, non-limiting examples of which include citrate/acetate, citrate/histidine, citrate/tartrate, histidine monohydrochloride, maleate/histidine, or succinate/histidine.
  • a composition of the invention which provides a long duration effect after treatment by a single injection includes a botulinum toxin, such as botulinum toxin A or botulinum toxin A of 150 kDa MW, as described herein, a positively charged carrier (or peptide) as described herein, a non-reducing disaccharide, such as sucrose, a non-ionic surfactant, such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or a sorbitan ester, and a physiologically compatible buffer, such as citric acid, acetic acid, succinic acid, tartaric acid, maleic acid, and histidine, which is capable of maintaining a suitable pH, such as a pH in the range of pH 4.5 to pH 6.5 or in the range of pH 4.5. to pH 7.5, in w/v amounts as described herein.
  • a botulinum toxin such as botulinum toxin A or botulinum toxin
  • a suitable composition to be used with described regimens comprises a botulinum toxin, e.g., a 150 kD toxin, a non-reducing disaccharide or a non-reducing tri saccharide, a non-ionic surfactant, a positively charged peptide carrier, and a physiologically compatible buffer for maintaining the pH between 4.5. and 7.5.
  • the concentration of the nonreducing sugar in the composition is in the range of 10% through 40% (w/v) and the concentration of the non-ionic surfactant is in the range of 0.005% through 0.5% (w/v).
  • the preferred composition comprises botulinum toxin, preferably botulinum toxin A, more preferably, of 150 kDa MW, a positively charged carrier (e.g., peptide) as described herein, a non-reducing disaccharide, such as sucrose, a non-ionic surfactant, such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or a sorbitan ester, and a physiologically compatible buffer, such as citric acid, acetic acid, succinic acid, tartaric acid, maleic acid, and histidine; and has a pH in the range of pH 4.5. to pH 7.5.
  • a positively charged carrier e.g., peptide
  • a non-reducing disaccharide such as sucrose
  • a non-ionic surfactant such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or a sorbitan ester
  • a physiologically compatible buffer such as citric acid,
  • a particular composition of the invention is an albumin-free composition which comprises a botulinum toxin, preferably botulinum toxin of serotype A, or a botulinum toxin A having a molecular weight of 150 kDa; a positively charged carrier (e.g., peptide such as that of SEQ ID NO: 4) at a ratio with toxin as described above; a non-reducing disaccharide or a nonreducing tri saccharide, preferably a di saccharide, present in a range of 10% through 40% (w/v); a non-ionic surfactant, preferably, a polysorbate or sorbitan ester, present in the range of 0.005% through 0.5% (w/v); and a physiologically compatible buffer, such as citric acid, acetic acid, succinic acid, tartaric acid, maleic acid, or histidine, present in the range of 0.400% to 0.600%; 0.450% to 0.575%, or 0.500% to a botul
  • Botulinum toxin formulations according to the invention can be delivered by injection (typically using a syringe) to muscles underlying the skin, or to glandular structures within the skin, in an effective amount to produce paralysis, produce relaxation, alleviate contractions, prevent or alleviate spasms, reduce glandular output, or other desired effects.
  • Local delivery of the botulinum toxin in this manner could afford dosage reductions, reduce toxicity and allow more precise dosage optimization for desired effects relative to injectable or implantable materials.
  • compositions of the invention are administered to deliver an effective amount, preferably a therapeutically effective amount, of the botulinum toxin.
  • effective amount or “therapeutically effective amount” as used herein means an amount of a botulinum toxin as defined above that is sufficient to produce the desired muscular paralysis or other biological effect, but that implicitly is a safe amount, i.e., one that is low enough to avoid serious side effects.
  • compositions of the invention may contain an appropriate effective amount of the botulinum toxin for application as a single-dose treatment, or may be more concentrated, either for dilution at the place of administration or for use in multiple applications and/or sequential applications over periods of time.
  • a botulinum toxin can be administered by injection to a subject for treating conditions such as cervical dystonia.
  • the botulinum toxin is administered by injection to muscles or to other skin- associated or other target tissue structures.
  • compositions are administered by or under the direction of a physician or other health care professional. They may be administered in a single treatment or in a series of treatments over time.
  • a composition according to the invention is injected at a location or locations where an effect associated with botulinum toxin is desired.
  • Table 1 provides guidance as to the appropriate dosage of RT002 for injection where a dose is 125 U or 250 U, respectively:
  • Table 1 -Injectable Muscles and Pre-defined RT002 for RT002 for Injection Volume by Muscle Injection 125 U Injection 250U
  • a total dose of 300 U, 350 U, 400 U, 450 U, or 500 U can be pro-rata adjusted from the above.
  • the one or more muscles in the head, neck, and shoulder area are injected with the botulinum toxin composition.
  • the one or more muscuclar targets are selected from a group consisting of the sternocleidomastoid, levator scapulae, scalenus complex, splenius capitis, splenius cervices, trapezius, and longissimus, the left and right side muscle or muscle complex each being an optional target, (see FIG. 11).
  • 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or all muscular targets are selected from a group consisting of sternocleidomastoid, levator scapulae, scalenus complex, splenius capitis, splenius cervices, trapezius, and longissimus, the left and right side muscle or muscle complex each being an optional target.
  • the splenius capitis, splenius cervices, trapezius, and longissimus may receive unilateral or bilateral injections (i.e., injections in one or both sides of the body).
  • only unilateral injections are administered in the sternocleidomastoid, levator scapulae, and/or scalenus complex.
  • the sternocleidomastoid, levator scapulae, scalenus complex, splenius capitis, splenius cervices, trapezius, and longissimus each receive at least one injection.
  • a muscular target can receive one or more injections, such as 1, 2, 3, 4, 5, etc.
  • the dosage range administered to each muscular target, by one or more injections is provided in Table 1.
  • the botulinum toxin preferably is administered at an amount, application rate, and frequency that will produce the desired result without producing any adverse or undesired results.
  • a single treatment with an effective dose of the compositions of the invention affords an effect of long duration such that during a course of treatment for an indication treatable by botulinum toxin, , or series of injections during a single multiple treatment session, with a concomitant effect that endures over extended periods of time, e g., at least 12. 14, 16, 18, 20, 24, 26, 28, 32, 36, and 38 weeks; or 3 months, 4 months, 5 months, 6 months or greater than 6 months, namely, 6 months, 7 months, 8 months, 9 months, or longer, including 10 months.
  • a therapeutically effective amount of toxin in a composition as described herein can be about 100 U to 500 U; or more specifically, from about 100U, 125U, 150U, 175U, 200U, 225U, 250U, 175U, 300U, 325U, 350U, 375U, 400U, 425U, 450U, or any amount therebetween of botulinum toxin.
  • the composition is DAXXIFY.
  • This invention also contemplates the use of a variety of delivery devices for injecting botulinum toxin-containing compositions described herein across skin.
  • delivery devices may include, without limitation, a needle and syringe, or may involve more sophisticated devices capable of dispensing and monitoring the dispensing of the composition, and optionally monitoring the condition of the subject in one or more aspects (e.g., monitoring the reaction of the subject to the substances being dispensed).
  • the compositions can be pre-formulated and/or pre-installed in a delivery device as such.
  • This invention also contemplates embodiments wherein the compositions are provided in a kit that stores one or more components separately from the remaining components.
  • the invention provides for a kit that separately stores botulinum toxin and the positively charged carrier for combining at or prior to the time of application.
  • the amount of positively charged carrier or the concentration ratio of these molecules to the botulinum toxin will depend on which carrier is chosen for use in the composition in question.
  • the appropriate amount or ratio of carrier molecule in a given case can readily be determined, for example, by conducting one or more experiments such as those described below.
  • the patient to be treated is 65 years of age, at least 65 years old, or over 65 years old.
  • the patient may be 65, 66, 68, 70, 75, 80 years, or older.
  • Example 1 An injectable botulinum toxin formulation (RT002) was prepared with ingredients according to Table 2 below. All inactive ingredients are listed in the US FDA inactive ingredients database, except for the novel excipient RTP004.
  • RTP004 is a peptide with the following sequence: RKKRRQRRRG-(K)i5-GRKKRRQRRR (SEQ ID NO: 4).
  • the botulinum toxin molecule is not covalently associated with R004.
  • RT002 does not contain accessory proteins or animal-derived proteins such albumin.
  • RT002 for Injection a , Theoretical amount of toxin required for 50U/vial drug product; b , Equivalent to 15 pg RTP004- Acetate; c , Water added in manufacturing is removed during the lyophilization step, d , Theoretical amount of toxin required for lOOU/vial drug product.
  • the recommended dose of DAXXIFY for the treatment of cervical dystonia ranged from 125 U to 250 U given intramuscularly as a divided dose among affected muscles. Subjects received an initial dose of either 125 U or 250 U of DAXXIFY.
  • the assigned dose either 125 U or 250 U — depended on whether the subject was previously treated with another botulinum toxin, their past dose, response to treatment, duration of effect, and adverse event history. For example, subjects were assigned 125 U if they previously received a BOTOX or XEOMIN dose that was less than 190 U, or they were assigned 250 U if they previously received a BOTOX or XEOMIN dose that was equal to or greater than 190 U.
  • FIG. 1 shows the muscles that would have been treated under the protocol.
  • TWSTRS Western Spamodic Torticollis Rating Scale
  • a subject was treated in accordance with the above protocol.
  • the subject presented with a baseline TW STRS score of about 50 before receiving their first treatment.
  • TWSTRS score decreased to 17 after 6 weeks, and to 15 after 12 weeks.
  • the patient received their second treatment at 20 weeks from initial treatment. At this time, the patient had experienced a 59% loss of effect from the initial treatment (i.e., 41% remaining efficacy).
  • the patient received their third treatment (18 weeks after the second treatment) and fourth treatment (22 weeks after the third treatment) with 63.0% and 23% efficacy remaining from the prior respective treatment.
  • the subject was treated with 125 U of DAXXIFY.
  • the TWSTRS scores during the course of these serial treatments are shown in FIG.
  • the peak efficacy trended “higher” i.e., a lower TWSTRS score
  • the patient exhibited an improvement in peak efficacy, evidenced by a TWSTRS score of 10.
  • the overlapping efficacy can cause a lowering of the peak effect over time at least for 3-4 treatment cycles.
  • Another benefit is that a patient will experience less symptom reemergence.
  • TWSTRS score stayed below 30 soon after the second treatment.
  • timing the dose of the third and fourth treatment during a period of significant efficacy from the prior treatment prevented the symptoms to reemerge to a significant degree.
  • the TWSTRS score exhibited a 60% change from before the first treatment to before the fourth treatment.
  • the patient’s experience is improved with a serial treatment protocol that administers a subsequent treatment with Daxxify® and its long duration of effect at an early phase of when the prior treatment begins to wane.
  • a subject was treated in accordance with the above protocol.
  • the TWSTRS scores during the course of these serial treatments are shown in FIG. 3.
  • the treatment interval was such that the subject was dosed near the peak efficacy, namely 77% remaining efficacy.
  • the subject was retreated at 28 and 48 weeks, and received a dose of 125 U of DAXXIFY each time.
  • the subject presented with a baseline TWSTRS score of 43 before the first treatment.
  • the subject’s peak efficacy decreased to a TWSTRS score of 13.
  • the patient Before receiving a second treatment, the patient presented with only a 26% loss of effect from the first treatment, and a TWSTRS score of about 19.
  • the patient had very little symptom reemergence, and the serial treatment protocol, wherein the patient was retreated when the patient was within 25% of the peak effect of the initial treatment, allowed for the patient to stay within 25% of the peak effect throughout the entire treatment cycles.
  • a subject was treated.
  • the protocol was the same as above except that the retreatment was closer to the return to baseline.
  • the TWSTRS scores during the course of these serial treatments are shown in FIG. 4.
  • the subject was retreated every 16 weeks, and received a dose of 250 U DAXXIFY each time.
  • the symptomatic state of the patient was not stable but was very close to baseline before retreatment.
  • a treatment interval for this patient in accordance with the present disclosure would have been dosed every 12 weeks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Les méthodes présentement décrites ici impliquent une série de sessions de traitement par une composition de toxine botulique qui peut être utilisée pour obtenir le maintien chez le patient d'un pic d'effet de traitement ou d'une plage étroite de celui-ci au cours d'une pluralité de sessions de traitement.
PCT/US2024/046938 2023-09-15 2024-09-16 Traitement en série par toxine botulique contre la dystonie cervicale WO2025059665A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363583215P 2023-09-15 2023-09-15
US63/583,215 2023-09-15
US202363583579P 2023-09-18 2023-09-18
US63/583,579 2023-09-18

Publications (1)

Publication Number Publication Date
WO2025059665A1 true WO2025059665A1 (fr) 2025-03-20

Family

ID=92973408

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/046938 WO2025059665A1 (fr) 2023-09-15 2024-09-16 Traitement en série par toxine botulique contre la dystonie cervicale

Country Status (1)

Country Link
WO (1) WO2025059665A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
EP1514556A1 (fr) 2000-02-08 2005-03-16 Allergan, Inc. Compositions pharmaceutiques à base de toxine botulique
US8623811B2 (en) 2007-07-26 2014-01-07 Revance Therapeutics, Inc. Antimicrobial peptide, compositions, and methods of use
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9340587B2 (en) 2009-06-25 2016-05-17 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
WO2018213710A1 (fr) 2017-05-18 2018-11-22 Revance Therapeutics, Inc. Procédés de traitement de la dystonie cervicale
WO2022081736A1 (fr) * 2020-10-13 2022-04-21 Revance Therapeutics, Inc. Méthodes de traitement de la dystonie cervicale

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
EP1514556A1 (fr) 2000-02-08 2005-03-16 Allergan, Inc. Compositions pharmaceutiques à base de toxine botulique
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8623811B2 (en) 2007-07-26 2014-01-07 Revance Therapeutics, Inc. Antimicrobial peptide, compositions, and methods of use
US9340587B2 (en) 2009-06-25 2016-05-17 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
WO2018213710A1 (fr) 2017-05-18 2018-11-22 Revance Therapeutics, Inc. Procédés de traitement de la dystonie cervicale
WO2022081736A1 (fr) * 2020-10-13 2022-04-21 Revance Therapeutics, Inc. Méthodes de traitement de la dystonie cervicale

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
@?ON BEHALF OF THE GLOBAL DYSPORT CERVICAL DYSTONIA STUDY GROUP ET AL: "Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia", PARKINSONISM AND RELATED DISORDERS, ELSEVIER SCIENCE, OXFORD, GB, vol. 16, no. 5, 1 June 2010 (2010-06-01), pages 316 - 323, XP027054548, ISSN: 1353-8020, [retrieved on 20100518] *
BRIN MITCHELL F. ET AL: "Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay", MOVEMENT DISORDERS, vol. 23, no. 10, 10 June 2008 (2008-06-10), US, pages 1353 - 1360, XP093228491, ISSN: 0885-3185, DOI: 10.1002/mds.22157 *
COLOSIMO CARLO ET AL: "Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: Findings from a prospective, observational study", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 416, 9 July 2020 (2020-07-09), XP086368265, ISSN: 0022-510X, [retrieved on 20200709], DOI: 10.1016/J.JNS.2020.117015 *
CONSOLE ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 35109
DEPASS, L.R., TOXICOL. LETTERS, vol. 49, 1989, pages 159 - 170
FLETCHER ET AL., CHEM. REV., vol. 98, 1998, pages 763
HOFFMAN, R.O. ET AL., INT. OPHTHALMOL. CLIN., vol. 26, 1986, pages 241 - 50
KESSLER, ANGEW. CHEM. INT. ED. ENGL., vol. 32, 1993, pages 543
PEARCE, L.B. ET AL., TOXICOL. APPL. PHARMACOL., vol. 128, 1994, pages 69 - 77
SIMON ET AL., PROC. NAT'L. ACAD. SCI. USA, vol. 89, 1992, pages 9367
SIMONETTA-MOREAU M ET AL: "Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport )", EUROPEAN JOURNAL OF NEUROLOGY, RAPID SCIENCE PUBLISHERS, GB, vol. 26, no. 6, 30 September 2018 (2018-09-30), pages 943 - e65, XP072031772, ISSN: 1351-5101, DOI: 10.1111/ENE.13800 *
ZUCKERMANN ET AL., CHEMTRACTS-MACROMOL. CHEM., vol. 4, 1992, pages 80

Similar Documents

Publication Publication Date Title
US20240058628A1 (en) Injectable botulinum toxin formulations
US12257293B2 (en) Methods of treatment for cervical dystonia
JP6955491B2 (ja) 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法
JP5690785B2 (ja) 改良されたボツリヌス毒素組成物
EP2413947B1 (fr) Procédé et composition de traitement des affections de la peau associées à une hyperréactivité vasculaire
US12161703B2 (en) Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
US20240269246A1 (en) Methods for treating cervical dystonia
WO2025059665A1 (fr) Traitement en série par toxine botulique contre la dystonie cervicale
WO2022178361A1 (fr) Procédés et compositions de traitement de la spasticité des membres supérieurs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24783834

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载